

B5

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/06459 A1

(51) International Patent Classification⁷: C12N 9/02, C12P 13/08, C12N 15/53

MOLENAAR, Douwe; Hofstrasse 12, Baesweiler 52499 (DE).

(21) International Application Number: PCT/EP01/05548

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 16 May 2001 (16.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

100 34 833.5 18 July 2000 (18.07.2000) DE
101 03 874.7 30 January 2001 (30.01.2001) DE

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: DEGUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE FERMENTATIVE PREPARATION OF L-THREONINE



WO 02/06459 A1



(57) Abstract: The invention provides a process for the fermentative preparation of L-threonine using Enterobacteriaceae which in particular already produce L-threonine and in which the nucleotide sequence(s) which code(s) for the mqo gene are enhanced, in particular over-expressed.

Process for the fermentative preparation of L-threonine

This invention relates to the new amino acid sequence of the malate:quinone oxidoreductase enzyme protein (Mqo) of Enterobacteriaceae and to a process for the fermentative preparation of L-threonine using Enterobacteriaceae in which the mqo gene is enhanced.

Prior Art

L-Threonine is used in animal nutrition, in human medicine and in the pharmaceuticals industry. It is known that L-threonine can be prepared by fermentation of strains of Enterobacteriaceae, in particular Escherichia coli and Serratia marcescens. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as e.g. stirring and supply of oxygen, or the composition of the nutrient media, such as e.g. the sugar concentration during the fermentation, or the working up to the product form by e.g. ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites, such as e.g. the threonine analogue α -amino- β -hydroxyvaleric acid (AHV), or are auxotrophic for metabolites of regulatory importance and produce L-threonine are obtained in this manner.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of Enterobacteriaceae strains which produce L-threonine, by amplifying individual threonine biosynthesis genes and investigating the effect on the L-threonine production.

Object of the Invention

The inventors had the object of providing new measures for improved fermentative preparation of L-threonine.

Description of the Invention

- 5 The invention provides a polypeptide from Enterobacteriaceae with malate:quinone oxidoreductase (Mqo) activity (E.C. 1.1.99.16) chosen from the group consisting of
 - a) polypeptide with the amino acid sequence shown in SEQ 10 ID NO. 2, or
 - b) polypeptide which is at least 70%, preferably at least 80%, particularly preferably at least 90 to 95% identical to the amino acid sequence shown in SEQ ID NO. 2, or
- 15 c) polypeptide according to SEQ ID NO. 2, including deletion, insertion or exchange of one or more amino acids, or
- d) polypeptide according to SEQ ID NO. 2, including N- or C-terminal lengthening by one or more amino acids,
- 20 the total length of the polypeptide according to b), c) or d) being at least 514 and at most 544, preferably at least 519 and at most 539, in a preferred form at least 524 and at most 534, particularly preferably at least 527 and at most 531 amino acid radicals.
- 25 The invention furthermore provides a polynucleotide from Enterobacteriaceae which codes for a polypeptide with malate:quinone oxidoreductase (Mqo) activity (E.C. 1.1.99.16), chosen from the group consisting of

- a) DNA which contains the nucleotide sequence corresponding to nucleobases 7 to 1593 of SEQ ID NO. 1, or
- b) DNA according to a) corresponding to the degeneration 5 of the genetic code, or
- c) DNA according to a) containing sense mutations of neutral function, or
- d) DNA which is at least 70%, preferably at least 80%, particularly preferably at least 90 to 95% identical to 10 that mentioned in a) or b), or
- e) polynucleotide which hybridizes with the DNA according to a), b), c) or d).

The invention also provides

- a DNA which is capable of replication and codes for the 15 polypeptide shown in SEQ ID NO. 2,
- a vector containing the mqo gene corresponding to nucleobases 7 to 1593 of SEQ ID NO. 1, in particular plasmid pMW218mqo shown in figure 1.

"Polynucleotide" in general relates to polyribonucleotides 20 and polydeoxyribonucleotides, it being possible for these to be non-modified RNA or DNA or modified RNA or DNA.

"Polypeptides" is understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.

25 The polypeptides according to the invention include the polypeptides according to SEQ ID NO. 2, which have malate:quinone oxidoreductase activity, and also those which are at least 70%, preferably at least 80% and in particular at least 90% to 95% identical to the polypeptide 30 according to SEQ ID NO. 2 and have the activity mentioned.

Finally, the invention provides a process for the fermentative preparation of L-threonine using Enterobacteriaceae which in particular already produce L-threonine and in which the nucleotide sequence(s) which 5 code(s) for the mqo gene are enhanced, in particular over-expressed.

In particular, the process is a process for the preparation of L-threonine, which comprises carrying out the following steps:

- 10 a) fermentation of microorganisms of the family Enterobacteriaceae in which at least the mqo gene is enhanced (over-expressed), optionally in combination with further genes,
- 15 b) concentration of the L-threonine in the medium or in the cells of the microorganisms of the family Enterobacteriaceae, and
- 16 c) isolation of the L-threonine.

The term "enhancement" in this connection describes the increase in the intracellular activity of one or more 20 enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or a gene which codes for a corresponding enzyme or protein with a high activity, and optionally combining these 25 measures.

The microorganisms which the present invention provides can 30 prepare L-threonine from glucose, sucrose, lactose, fructose, maltose, molasses, starch; or from glycerol and ethanol. They are representatives of Enterobacteriaceae, in particular of the genera Escherichia and Serratia. Of the genus Escherichia the species E. coli and of the genus Serratia the species Serratia marcescens are to be mentioned in particular.

Suitable L-threonine-producing strains of the genus *Escherichia*, in particular of the species *E. coli*, are, for example

- 5 *Escherichia coli* TF427
- Escherichia coli* H4578
- Escherichia coli* KY10935
- Escherichia coli* EL1003
- Escherichia coli* VNIIgenetika MG-442
- Escherichia coli* VNIIgenetika VL334/pYN7
- 10 *Escherichia coli* VNIIgenetika M1
- Escherichia coli* VNIIgenetika 472T23
- Escherichia coli* VNIIgenetika TDH-6
- Escherichia coli* BKIIM B-3996
- Escherichia coli* BKIIM B-5318
- 15 *Escherichia coli* B-3996-C43
- Escherichia coli* B-3996-C80
- Escherichia coli* B-3996/pTWV-pps
- Escherichia coli* B-3996(pMW::THY)
- Escherichia coli* B-3996/pBP5
- 20 *Escherichia coli* kat 13
- Escherichia coli* KCCM-10132

Suitable L-threonine-producing strains of the genus *Serratia*, in particular of the species *Serratia marcescens*, are, for example

- 25 *Serratia marcescens* HNr21
- Serratia marcescens* TLr156
- Serratia marcescens* T2000.

The nucleotide sequence of the chromosome of *E. coli* is known and is available in databanks accessible to the public, such as, for example, the databank of the European Molecular Biology Laboratories (EMBL, Heidelberg, Germany).

Examples of such sequences deposited are the entries accessible under number AE000310 or D90850.

In the work on the present invention it was possible to identify the *mgo* gene, which codes for malate:quinone oxidoreductase, of *E. coli* (SEQ ID NO. 1) and the amino acid sequence of the *Mgo* enzyme protein formed (SEQ ID NO. 2).

It has furthermore been possible to isolate two further new malate:quinone oxidoreductase proteins, designated protein B 10 and C, which have the N-terminal amino acid sequence shown in SEQ ID No. 11 and 12. These are also provided by the invention.

It has been found that *Enterobacteriaceae* produce L-threonine in an improved manner after over-expression of 15 the *mgo* gene, which codes for malate:quinone oxidoreductase (E.C. 1.1.99.16).

According to the invention, it is also possible to use a DNA section which contains the DNA sequence of the gene of the malate:quinone oxidoreductase given in the databank of 20 the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA) with accession number P33940.

Alleles of the *mgo* gene which result from the degeneracy of the genetic code or due to "sense mutations" of neutral function can furthermore be used. It is also known that 25 the amino acid methionine or formylmethionine coded by the start codon ATG can be removed in various proteins by enzymes of the host.

To achieve an over-expression, the number of copies of the corresponding genes can be increased, or the promoter and 30 regulation region or the ribosome binding site upstream of the structural gene can be mutated. Expression cassettes which are incorporated upstream of the structural gene act in the same way. By inducible promoters, it is

additionally possible to increase the expression in the course of fermentative L-threonine production. The expression is likewise improved by measures to prolong the life of the m-RNA. Furthermore, the enzyme activity is 5 also increased by preventing the degradation of the enzyme protein. The genes or gene constructions can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome. Alternatively, an over-expression of the genes in question 10 can furthermore be achieved by changing the composition of the media and the culture procedure.

Instructions in this context can be found by the expert, *inter alia*, in Chang and Cohen (Journal of Bacteriology 134:1141-1156 (1978)), in Hartley and Gregori (Gene 13:347-15 353 (1981)), in Amann and Brosius (Gene 40:183-190 (1985)), in de Broer et al. (Proceedings of the National (sic) of Sciences of the United States of America 80:21-25 (1983)), in LaVallie et al. (BIO/TECHNOLOGY 11, 187-193 (1993)), in WO 98/04715, in Llosa et al. (Plasmid 26:222-224 (1991)), 20 in Quandt and Klipp (Gene 80:161-169 (1989)), in Hamilton (Journal of Bacteriology 171:4617-4622 (1989)), in Jensen and Hammer (Biotechnology and Bioengineering 58, 191-195 (1998) and in known textbooks of genetics and molecular biology.

25 Plasmid vectors which are capable of replication in Enterobacteriaceae, such as e.g. cloning vectors derived from pACYC184 (Bartolomé et al.; Gene 102, 75-78 (1991)), pTrc99A, which is described by Amann et al. (Gene 69:301-315 (1988)), or pSC101 derivatives (Vocke and Bastia, 30 Proceedings of the National Academy of Science, USA 80 (21):6557-6561 (1983)) can be used. A strain transformed with a plasmid vector where the plasmid vector carries the nucleotide sequence which codes for the mqo gene can be employed in a process according to the invention.

In addition, it may be advantageous for the production of L-threonine with strains of the family Enterobacteriaceae to enhance, in particular to over-express, one or more enzymes of the known threonine biosynthesis pathway or 5 enzymes of anaplerotic metabolism or enzymes for the production of reduced nicotinamide adenine dinucleotide phosphate, in addition to the *mgo* gene.

Thus, for example, one or more genes chosen from the group consisting of

- 10 • the *thrABC* operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),
- the *pyc* gene which codes for pyruvate carboxylase (DE-A-19 831 609),
- 15 • the *pps* gene which codes for phosphoenol pyruvate synthase (Molecular and General Genetics 231:332 (1992)),
- the *ppc* gene which codes for phosphoenol pyruvate carboxylase (Gene 31:279-283 (1984)),
- 20 • the genes *pntA* and *pntB* which code for transhydrogenase (European Journal of Biochemistry 158:647-653 (1986)),
- the *rhtB* gene which imparts homoserine resistance (EP-A-0994190)
- 25 • the *rhtC* gene which imparts threonine resistance (EP-A-1013765), and
- the *gdhA* gene which codes for glutamate dehydrogenase (Gene 27:193-199 (1984))

can be enhanced, in particular over-expressed, at the same time.

It may furthermore be advantageous for the production of L-threonine, in addition to the enhancement of the mqo gene, for one or more of the genes chosen from the group consisting of:

- 5 • the tdh gene which codes for threonine dehydrogenase (Ravnikar and Somerville, Journal of Bacteriology 169, 4716-4721 (1987)),
- the mdh gene which codes for malate dehydrogenase (E.C. 1.1.1.37)
- 10 to be attenuated, in particular to be eliminated or for the expression thereof to be reduced at the same time.

Finally, in addition to enhancement of the mqo gene it may be advantageous for the production of L-threonine to eliminate undesirable side reactions, (Nakayama: "Breeding 15 of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982). Bacteria in which the metabolic pathways which reduce the formation of L-threonine are at least partly eliminated can be employed in 20 a process according to the invention.

The microorganisms produced according to the invention can be cultured in the batch process (batch culture) or in the fed batch process (feed process). A summary of known culture methods is described in the textbook by Chmiel 25 (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik [Bioprocess Technology 1. Introduction to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen [Bioreactors and Peripheral 30 Equipment] (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained

in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).

Sugars and carbohydrates, such as e.g. glucose, sucrose, 5 lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic 10 acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.

Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep 15 liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulphate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.

20 Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus. The culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, 25 which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the abovementioned substances. Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to 30 the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed

in a suitable manner to control the pH. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, e.g. antibiotics, can be added 5 to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 25°C to 45°C, and preferably 30°C to 40°C. Culturing is continued 10 until a maximum of L-threonine has formed. This target is usually reached within 10 hours to 160 hours.

The analysis of L-threonine can be carried out by anion exchange chromatography with subsequent ninhydrin derivatization, as described by Spackman et al. (Analytical 15 Chemistry, 30, (1958), 1190), or it can take place by reversed phase HPLC as described by Lindroth et al. (Analytical Chemistry (1979) 51: 1167-1174).

A pure culture of the L-threonine-producing strain B-3996kurΔtdh/pVIC40, pMW218mqo was deposited on 24th 20 January 2001 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) as DSM 14004.

The process according to the invention is used for the 25 fermentative preparation of amino acids, in particular L-threonine and L-isoleucine.

The present invention is explained in more detail in the following with the aid of embodiment examples.

The isolation of plasmid DNA from *E. coli* and all 30 techniques of restriction, Klenow and alkaline phosphatase treatment are carried out by the method of Sambrook et al. (Molecular cloning - A laboratory manual (1989) Cold Spring Harbour Laboratory Press). Unless described otherwise, the

transformation of *E. coli* is carried out by the method of Chung et al. (Proceedings of the National Academy of Sciences of the United States of America USA (1989) 86:2172-2175).

5 The incubation temperature during preparation of strains and transformants is 37°C. Temperatures of 30°C and 44°C are used in the gene replacement process according to Hamilton et.al.

Example 1

10 Construction of the expression plasmid pMW218mqo

The mqo gene from *E. coli* K12 is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence of the yojH gene in *E. coli* K12 MG1655 (EMBL AE000310), PCR 15 primers (see SEQ ID No. 3 and 4) are synthesized (MWG Biotech, Ebersberg, Germany):

YojH1: 5' - GCGGAATTCGATGGCGGCAAAAGCG - 3'

YojH2: 5' - GTTACGCCGCATCCAACATC - 3'

The chromosomal *E. coli* K12 MG1655 DNA employed for the PCR 20 is isolated according to the manufacturers instructions with "QIAGEN Genomic-tips 100/G" (QIAGEN, Hilden, Germany). A DNA fragment approx. 1700 base pairs (bp) in size can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR protocols. A guide to 25 methods and applications, Academic Press) with Pfu-DNA polymerase (Promega Corporation, Madison, USA). The PCR product is cleaved with the enzyme EcoRI and ligated with the plasmid pMW218 (Nippon Gene, Toyama, Japan), which is cleaved with the enzymes EcoRI and SmaI. The *E. coli* 30 strain DH5 α is transformed with the ligation batch and plasmid-carrying cells are selected on LB agar (Lennox, Virology 1:190 (1955)), to which 20 μ g/ml kanamycin is

added. Successful cloning of the mqo gene can be demonstrated after plasmid DNA isolation and control cleavage with EcoRI, AccI and ClaI. The plasmid is designated pMW218mqo (figure 1).

5 Example 2

Preparation of L-threonine with the strain MG442/pMW218mqo

2.1 Preparation of the strain MG442/pMW218mqo

The L-threonine-producing *E. coli* strain MG442 is described in US-A- 4,278,765 and deposited as CMIM B-1628 at the 10 Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia).

The strain MG442 is transformed with the plasmid pMW218mqo and plasmid-carrying cells are selected on LB agar supplemented with 20 µg/ml kanamycin. The strain is 15 designated MG442/pMW218mqo.

2.2 Preparation of L-threonine

Selected individual colonies of MG442/pMW218mqo are multiplied further on minimal medium with the following composition: 3.5 g/l Na₂HPO₄*2H₂O, 1.5 g/l KH₂PO₄, 1 g/l 20 NH₄Cl, 0.1 g/l MgSO₄*7H₂O, 25 mg/l isoleucine, 2 g/l glucose, 20 g/l agar, 20 mg/l kanamycin. The formation of L-threonine is checked in batch cultures of 10 ml contained in 100 ml conical flasks. For this, 10 ml of preculture medium of the following composition: 2 g/l yeast extract, 25 10 g/l (NH₄)₂SO₄, 1 g/l KH₂PO₄, 0.5 g/l MgSO₄*7H₂O, 15 g/l CaCO₃, 20 g/l glucose, 20 mg/l kanamycin are inoculated and the batch is incubated for 16 hours at 37°C and 180 rpm on an ESR incubator from Kühner AG (Birsfelden, Switzerland). In each case 250 µl of this preculture are transinoculated 30 into 10 ml of production medium (25 g/l (NH₄)₂SO₄, 2 g/l KH₂PO₄, 1 g/l MgSO₄*7H₂O, 0.03 g/l FeSO₄*7H₂O, 0.018 g/l MnSO₄*1H₂O, 25 mg/l isoleucine, 30 g/l CaCO₃, 20 g/l

glucose) and the batch is incubated for 48 hours at 37°C. After the incubation the optical density (OD) of the culture suspension is determined with an LP2W photometer from the company Dr. Lange (Berlin, Germany) at a 5 measurement wavelength of 660 nm.

The concentration of L-threonine formed is then determined in the sterile-filtered culture supernatant with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column reaction 10 with ninhydrin detection.

The result of the experiment is shown in Table 1.

Table 1

Strain	OD (660 nm)	L-Threonine g/l
MG442	4.7	0.46
MG442/pMW218mqo	4.5	0.89

Example 3

15 Preparation of L-threonine with the strain
B-3996kurΔtdh/pVIC40, pMW218mqo

The L-threonine-producing *E. coli* strain B-3996 is described in US-A- 5,175,107 and deposited at the Russian National Collection for Industrial Microorganisms (VKPM, 20 Moscow, Russia).

3.1 Preparation of the strain B-3996kurΔtdh/pVIC40,
pMW218mqo

After culture in antibiotic-free complete medium for approximately ten generations, a derivative of strain B- 25 3996 which no longer contains the plasmid pVIC40 is

isolated. The strain formed is streptomycin-sensitive and is designated B-3996kur.

The method described by Hamilton et al. (Journal of Bacteriology (1989) 171: 4617-4622), which is based on the 5 use of the plasmid pMAK705 with a temperature-sensitive replicon, is used for incorporation of a deletion into the tdh gene. The plasmid pDR121 (Ravnikar and Somerville, Journal of Bacteriology (1987) 169:4716-4721) contains a DNA fragment from *E. coli* 3.7 kilo-base pairs (kbp) in 10 size, on which the tdh gene is coded. To generate a deletion of the tdh gene region, pDR121 is cleaved with the restriction enzymes *Cla*I and *Eco*RV and the DNA fragment 5 kbp in size isolated is ligated, after treatment with Klenow enzyme. The ligation batch is transformed in the *E.* 15 *coli* strain DH5 α and plasmid-carrying cells are selected on LB agar, to which 50 μ g/ml ampicillin are added.

Successful deletion of the tdh gene can be demonstrated after plasmid DNA isolation and control cleavage with *Eco*RI. The *Eco*RI fragment 1.7 kbp in size is isolated, and 20 ligated with the plasmid pMAK705, which is partly digested with *Eco*RI. The ligation batch is transformed in DH5 α and plasmid-carrying cells are selected on LB agar, to which 20 μ g/ml chloramphenicol are added. Successful cloning is demonstrated after isolation of the plasmid DNA and 25 cleavage with *Eco*RI. The pMAK705 derivative formed is designated pDM32.

For the gene replacement, B-3996kur is transformed with the plasmid pDM32. The replacement of the chromosomal tdh gene with the plasmid-coded deletion construct is carried out by 30 the selection process described by Hamilton et al. and is verified by standard PCR methods (Innis et al. (1990), PCR Protocols. A Guide to Methods and Applications, Academic Press) with the following oligonucleotide primers (see SEQ ID No. 5 and 6).

Tdh1: 5'-TCGCGACCTATAAGTTGGG-3'

Tdh2: 5'-AATACCAGCCCTTGTTCGTG-3'.

The strain formed is tested for kanamycin sensitivity and is designated B-3996kurΔtdh.

5 B-3996kurΔtdh is transformed with the plasmid pVIC40 isolated from B-3996 and plasmid-carrying cells are selected on LB agar with 20 µg/ml streptomycin. A selected individual colony is designated B-3996kurΔtdh/pVIC40 and transformed with the plasmid pMW218mqa. Selection is

10 carried out on LB-agar to which 20 µg/ml streptomycin and 50 µg/ml kanamycin are added. The strain formed in this way is designated B-3996kurΔtdh/pVIC40, pMW218mqa.

3.2 Preparation of L-threonine

The preparation of L-threonine by the strains

15 B-3996kurΔtdh/pVIC40 and B-3996kurΔtdh/pVIC40, pMW218mqa is tested as described in example 2, the minimal medium and the production medium not being supplemented with L-isoleucine. The minimal medium, the preculture medium and the production medium are supplemented with 20 µg/ml

20 streptomycin for B-3996kurΔtdh/pVIC40 and with 20 µg/ml streptomycin and 50 µg/ml kanamycin for B-3996kurΔtdh/pVIC40, pMW218mqa.

The result of the experiment is summarized in Table 2.

Table 2

Strain	OD (660 nm)	L- Threonine
B-3996kurΔtdh/pVIC40	4.7	6.26
B-3996kurΔtdh/pVIC40, pMW218mqa	3.7	7.72

Example 4

Preparation of a vector containing a histidine-tagged malate:quinone oxidoreductase gene of *E. coli*

A 1744 bp DNA fragment, which codes for the malate:quinone oxidoreductase protein extended by a six-fold histidine radical on the C-terminal end, was prepared by means of the polymerase chain reaction (PCR) and then cloned.

The primer YOJH1a (SEQ ID No 7) was drafted with the aid of the known nucleotide sequence with Accession Number 10 AE000310 (EMBL, European Molecular Biology Laboratories, Heidelberg, Germany). This primer has the sequence:

5`-GGA TCC GTT GAT GCC GCG CAA ATC-3`.

The primer YCHIS (SEQ ID No 8), which has the following sequence, was employed as the second primer:

15 5`-CGC GAA TTC TTA GTG GTG GTG GTG GTG GTG CAA CGC AAT ATC CGC CAC-3`.

The primers shown were synthesized by MWG Biotech (Ebersberg, Germany). The PCR reaction was carried out by the standard PCR method of Innis et al., (PCR Protocols. A 20 Guide to Methods and Applications, 1990, Academic Press, New York, USA).

Whole DNA isolated from a colony of the *E. coli* strain MC4100 (Casadaban et al. Journal of Molecular Biology 104, 541-555, 1976) served as the template.

25 The PCR was carried out in a Thermocycler from Techne (Cambridge, UK). The samples were first denatured for 5 minutes at 94°C and the Taq polymerase from Promega (Madison, WI, USA) was then added to the sample batch. A cycle comprising denaturing (60 seconds, 94°C), annealing 30 (60 seconds, 60°C) and synthesis (120 seconds, 72°C) was then passed through 10 times, the annealing temperature

being increased by 0.4°C in each cycle. The subsequent 25 cycles comprised denaturing (60 seconds, 94°C), annealing (60 seconds, 64°C) and synthesis (120 seconds, 72°C). Finally, a concluding synthesis of 10 minutes at 72°C was 5 carried out.

The DNA fragment 1744 bp in length containing the mqo gene amplified in this manner was purified with the aid of the QIAQuick PCR Purification Kit from Qiagen (Hilden, Germany) and then digested with the restriction enzymes BamHI and 10 EcoRI. These restriction cleavage sites were generated during the PCR with the aid of the primers YOJHI and YCHIS. After gel electrophoresis, the digested DNA fragment was cut out of the agarose gel and purified with QIAEX II Gel Extraction Kit (155) (Hilden, Germany), mixed into the 15 vector pUC19 treated with the restriction enzymes BamHI and EcoRI (Yanisch-Perron et al., Gene 33, 103-119, 1985) and then treated with T4 DNA ligase.

An E. coli strain designated MC4100Δmqo, which contains a deletion in the mqo gene and was prepared according to the 20 prior art, was used as the cloning host for the transformation. For this, the mqo gene was first amplified with the aid of the primers Y_01 (SEQ ID No 9) and Y_04 (SEQ ID No 10) using whole DNA isolated from strain MC4100, with the aid of the PCR method. The PCR conditions 25 comprised 30 cycles of denaturing (30 seconds, 94°C), annealing (30 seconds, 60°C) and synthesis (2 minutes, 72°C).

The primer Y_01 has the following sequence:

5`-GCTGGATGAATGGGCAGCGG-3`

30 The primer Y_04 has the following sequence:
5`-CGCGGGATCCCCGGTTCAACGATGATG-3`

The amplified DNA fragment contains a cleavage site for the restriction enzyme BamHI directly after the primer Y_01.

The BamHI restriction cleavage site contained in the oligonucleotide primer Y_04 is identified by underlining. The amplified DNA fragment was digested with BamHI and then incorporated into the BamHI cleavage site of the plasmid 5 pKO3 described by Link et al. (Journal of Bacteriology 179, 6228-6237 (1997)). The resulting plasmid was designated pKO3mqo and treated with the restriction enzyme MluI in order to remove an internal DNA segment of the mqo gene 416 bp long (deletion). The plasmid pKO3Δmqo obtained in this 10 manner was used for incorporation of the deletion Δmqo in the strain MC4100. The method described by Link et al (Journal of Bacteriology 179, 6228-6237 (1997)) was employed for this.

The strain MC4100Δmqo was transformed with the ligation 15 mixture described above. Transformants were selected on LB medium, which had been supplemented with 100 μ g/ml carbenicillin. A plasmid was isolated from a transformant and designated pUCH2. Plasmid pUCH2 contains a DNA fragment 1744 bp long, which codes for the malate:quinone 20 oxidoreductase protein extended by a six-fold histidine radical on the C-terminal end.

Example 5

Isolation and purification of the over-expressed histidine-tagged malate:quinone oxidoreductase

25 Five times, 200 ml LB medium were treated with 100 μ g/ml carbenicillin and 100 μ M isopropyl β -D-thiogalactoside (IPTG), inoculated with in each case a colony of the strain MC4100Δmqo/pUCH2 and in each case cultured in 1 l conical flasks for 16 hours at 37°C and 200 revolutions per minute. 30 The cells were washed twice in buffer A (50 mM hepes, 10 mM potassium acetate, 10 mM CaCl₂, 5 mM MgCl₂, adjusted to pH 7.5 with NaOH) at 4°C and resuspended in 40 ml of the same buffer. The cells were then broken down twice in a precooled French Pressure Cell from Spectronic Unicam

(Rochester, NY, USA) under 69 MPa (mega-Pascal). The cell debris was then sedimented twice in a centrifuge at 4°C for 10 minutes at 10000 x g. The supernatant was then centrifuged for 30 minutes at 75000 x g and 4°C. The 5 membrane pellet was resuspended with the same volume of buffer B (50 mM Na phosphate, 200 mM NaCl, pH 7.5) and centrifuged again for 30 minutes at 75000 x g and 4°C. The pellet was then resuspended with 1 ml buffer B. The histidine-tagged malate:quinone oxidoreductase protein was 10 purified in two steps.

Step 1: Solubilization:

2 % Triton X-100 and 10 % glycerol were added to the resuspended membranes and the batch was incubated for 10 minutes on ice. The batch was then centrifuged for 30 15 minutes at 200000 x g at 4°C.

Step 2: Affinity chromatography:

The equilibration of the "Talon-Metal-Affinity Resin" column material (500 µl column volume, CLONTECH Laboratories, Palo Alto, USA) was carried out twice with 20 1 ml buffer B and once with 1 ml buffer C (50 mM Na phosphate, 200 mM NaCl, 0.05 % Triton X-100, 10 µM flavin adenine dinucleotide (FAD), 0.2 mg/ml phospholipid, pH 7.0). The phospholipid used was L- α phosphatidylethanolamine, type IX from *E. coli* (Sigma- 25 Aldrich, Deisenhofen, Germany), which was mixed as a 30 mg/ml stock solution in deionized water and treated briefly with an ultrasound apparatus (BRANSON Sonifier Cell Disrupter B15) for a few seconds until the suspension was transparent. The supernatant (1 ml) from step 1 was 30 applied to the equilibrated column and incubated for 20 minutes at room temperature. Thereafter, the column was flushed five times with buffer D (50 mM Na phosphate, 200 mM NaCl, 0.05 % Triton X-100, 10 % glycerol, 10 µM FAD, 0.2 mg/ml phospholipid, 10 mM imidazole, pH 7.0) and then

eluted twice with 500 μ l buffer E (50 mM Na phosphate, 200 mM NaCl, 0.05 % Triton X-100, 10 % glycerol, 10 μ M FAD, 0.2 mg/ml phospholipid, 100 mM imidazole, pH 7.0). The two fractions were combined and a buffer exchange was carried 5 out by means of an ULTRAFREE-0.5 Centrifugal Filter Device (Millipore Corporation, Bedford, MA, USA), in order to remove the imidazole and to reduce the volume to 500 μ l. A second affinity chromatography was then carried out with the "Talon-Metal-Affinity Resin" column material (250 μ l 10 column volume), as described above. The purified protein was stored at -20°C.

The purified malate:quinone oxidoreductase protein was investigated by means of SDS polyacrylamide gel electrophoresis and subsequent staining with Coomassie 15 blue. In this analysis, two protein bands (protein B and protein C) with the mobility corresponding to a molecular weight of about 60 \pm 2 KD (kilo-Dalton) were detected. The two proteins were blotted on to a polyvinylidene difluoride (PVDF) membrane (Boehringer Mannheim, Mannheim, Germany) 20 and stained with Coomassie blue. The two protein bands were then cut out of the blot membrane.

Example 6

Determination of the N-position amino acid sequence

The N-position amino acid sequences of the malate:quinone 25 oxidoreductase protein B and protein C were determined by Edman degradation (Edman, Molecular Biology Biochemistry Biophysics 8:211-55(1970)) by means of the automatic sequencer Procise Sequencer from PE Biosystems (Foster City, CA, USA). For protein B the amino acid sequence L N 30 A V S M (see also SEQ ID No. 11) and for protein C the amino acid sequence A V S M A A K (see also SEQ ID No. 12) was determined.

Brief Description of the Figures:

Figure 1: Map of the plasmid pMW218mqo containing the mqo gene.

The length data are to be understood as approx. data. The
5 abbreviations and designations used have the following
meaning:

- Plac: Promoter sequence of the lactose operon
- Kan: Kanamycin resistance gene

The abbreviations for the restriction enzymes have the
10 following meaning

- AccI: Restriction endonuclease from *Acinetobacter calcoaceticus*
- ClaI: Restriction endonuclease from *Caryphanon latum*
- EcoRI: Restriction endonuclease from *E. coli*
- 15 • KpnI: Restriction endonuclease from *Klebsiella pneumoniae*
- SalI: Restriction endonuclease from *Streptomyces albus*

What is claimed is:

1. A polypeptide from Enterobacteriaceae with malate:quinone oxidoreductase (Mqo) activity (E.C. 1.1.99.16) chosen from the group consisting of
 - 5 a) polypeptide with the amino acid sequence shown in SEQ ID NO. 2, or
 - b) polypeptide which is at least 70%, preferably at least 80%, particularly preferably at least 90 to 95% identical to the amino acid sequence shown in
- 10 10 SEQ ID NO. 2, or
- c) polypeptide according to SEQ ID NO. 2, including deletion, insertion or exchange of one or more amino acids, or
- d) polypeptide according to SEQ ID NO. 2, including N-15 or C-terminal lengthening by one or more amino acids,

the total length of the polypeptide according to b), c) or d) being at least 514 and at most 544, preferably at least 519 and at most 539, in a preferred form at least 20 524 and at most 534, particularly preferably at least 527 and at most 531 amino acid radicals.

2. A polynucleotide from Enterobacteriaceae which codes for a polypeptide with malate:quinone oxidoreductase (Mqo) activity (E.C. 1.1.99.16), chosen from the group 25 consisting of
 - a) DNA which contains the nucleotide sequence corresponding to nucleobases 7 to 1593 of SEQ ID NO. 1, or
 - b) DNA according to a) corresponding to the 30 degeneration of the genetic code, or

- c) DNA according to a) containing sense mutations of neutral function, or
- d) DNA which is at least 70%, preferably at least 80%, particularly preferably at least 90 to 95% identical to that mentioned in a) or b), or

5 e) polynucleotide which hybridizes with the DNA according to a), b), c) or d).

3. A polynucleotide as claimed in claim 2, which is DNA which is capable of replication and codes for the

10 polypeptide shown in SEQ ID NO. 2.

4. The plasmid pMW218mqo which contains the mqo gene of *Escherichia coli*.

5. A process for the fermentative preparation of L-threonine, which comprises employing Enterobacteriaceae

15 bacteria, in particular those which already produce L-threonine and in which the nucleotide sequence(s) which code(s) for the mqo gene are enhanced, in particular over-expressed.

6. A process as claimed in claim 5, wherein further genes

20 are enhanced in addition to the mqo gene.

7. A process as claimed in claim 5 or 6, wherein the microorganisms of the family Enterobacteriaceae are from the genus *Escherichia* and *Serratia*.

8. A process as claimed in claim 7, wherein the

25 microorganisms are from the genus *Escherichia*, in particular of the species *Escherichia coli*.

9. A process as claimed in claim 5, wherein the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase


30 is enhanced at the same time.

10. A process as claimed in claim 5, wherein the pyc gene which codes for pyruvate carboxylase is enhanced at the same time.
11. A process as claimed in claim 5, wherein the pps gene 5 which codes for phosphoenol pyruvate synthase is enhanced at the same time.
12. A process as claimed in claim 5, wherein the ppc gene which codes for phosphoenol pyruvate carboxylase is enhanced at the same time.
- 10 13. A process as claimed in claim 5, wherein the genes pntA and pntB which code for transhydrogenase are enhanced at the same time.
14. A process as claimed in claim 5, wherein the gene rhtB which imparts homoserine resistance is enhanced at the 15 same time.
15. A process as claimed in claim 5, wherein bacteria in which the metabolic pathways which reduce the formation of L-threonine are at least partly eliminated are employed.
- 20 16. A process as claimed in claim 5, wherein a strain transformed with a plasmid vector is employed and the plasmid vector carries the nucleotide sequence which codes for the mqo gene can be employed.
17. A process as claimed in claim 5, wherein bacteria 25 transformed with the plasmid pMW218mqo are employed.
18. A process as claimed in claim 5, wherein the expression of the mqo gene is optionally induced with isopropyl β -D-thiogalactoside.
19. A process as claimed in claim 5, wherein at the same 30 time the gdhA gene which codes for glutamate dehydrogenase is enhanced.

20. A process as claimed in claim 5, wherein at the same time the *rhtC* gene which imparts threonine resistance is enhanced.
21. A process as claimed in claim 5, wherein the nucleotide 5 sequence codes for a malate:quinone oxidoreductase protein with the N-terminal amino acid sequence Met Ala Ala Lys Ala Lys corresponding to SEQ ID No. 2.
22. A process as claimed in claim 5, wherein the nucleotide sequence codes for a malate:quinone oxidoreductase 10 protein with the N-terminal amino acid sequence Leu Asn Ala Val Ser Met according to SEQ ID no. 11.
23. A process as claimed in claim 5, wherein the nucleotide sequence codes for a malate:quinone oxidoreductase protein with the N-terminal amino acid sequence Ala Val 15 Ser Met Ala Ala Lys according to SEQ ID No. 12.
24. A process for the preparation of L-threonine, which comprises carrying out the following steps:
 - a) fermentation of microorganisms of the family Enterobacteriaceae in which at least the *mgo* gene 20 is enhanced (over-expressed), optionally in combination with further genes,
 - b) concentration of the L-threonine in the medium or in the cells of the microorganisms of the family Enterobacteriaceae, and
25. d[sic]) isolation of the L-threonine.
26. A malate-quinone oxidoreductase protein from Enterobacteriaceae with the N-terminal amino acid sequence according to SEQ ID No. 11.
30. A malate:quinone oxidoreductase protein from Enterobacteriaceae with the N-terminal amino acid sequence according to SEQ ID No. 12.

27. An L-threonine-producing strain of the genus Escherichia with the genetic and phenotypic features of the strain B-3996kurΔtdh/pVIC40, pMW218mqo.
28. The L-threonine-producing Escherichia coli strain B-3996kurΔtdh/pVIC40, pMW218mqo deposited as. (sic) DSM 14004.

Figure 1:



SEQUENCE PROTOCOL

<110> Degussa AG

5 <120> Process for the fermentative preparation of L-threonine.

<130> 000323 BT

10 <140>

10 <141>

<160> 12

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 1720

<212> DNA

<213> Escherichia coli

20

<220>

<221> CDS

<222> (7)..(1593)

<223> mqo gene

25

<400> 1

aattcg atg gcg gca aaa gcg aaa gcg tcc gag gag cag gaa act gat	48
Met Ala Ala Lys Ala Lys Ala Ser Glu Glu Gln Glu Thr Asp	
1 5 10	

30

gta ctg ttg att ggc ggc ggc att atg agc gcc acg ttg ggg acc tat	96
Val Leu Leu Ile Gly Gly Ile Met Ser Ala Thr Leu Gly Thr Tyr	
15 20 25 30	

35

tta cgc gag ctg gag cct gaa tgg tcg atg acc atg gtg gag cgc ctg	144
Leu Arg Glu Leu Glu Pro Glu Trp Ser Met Thr Met Val Glu Arg Leu	
35 40 45	

40

gag ggt gtc gcg cag gag agt tcg aac ggc tgg aat aac gcc gga acc	192
Glu Gly Val Ala Gln Glu Ser Ser Asn Gly Trp Asn Asn Ala Gly Thr	
50 55 60	

45

ggg cat tct gca ctg atg gaa ctg aac tac acc ccc caa aac gcc gat	240
Gly His Ser Ala Leu Met Glu Leu Asn Tyr Thr Pro Gln Asn Ala Asp	
65 70 75	

50

ggc agc atc agt att gaa aaa gca gtc gcc att aac gaa gca ttt cag	288
Gly Ser Ile Ser Ile Glu Lys Ala Val Ala Ile Asn Glu Ala Phe Gln	
80 85 90	

att tcc cgc cag ttc tgg gcg cac cag gtt gag cgc ggc gtg ctg cgt	336
Ile Ser Arg Gln Phe Trp Ala His Gln Val Glu Arg Gly Val Leu Arg	
95 100 105 110	

act ccg cgt tca ttt atc aat acc gtt ccg cat atg agc ttt gtc tgg	384
Thr Pro Arg Ser Phe Ile Asn Thr Val Pro His Met Ser Phe Val Trp	
115 120 125	

ggc gag gat aac gtc aat ttc ctg cgc gcc cgt tac gcc gcg ttg caa	432
Gly Glu Asp Asn Val Asn Phe Leu Arg Ala Arg Tyr Ala Ala Leu Gln	
130 135 140	

caa	agc	tcg	ctg	ttt	cgc	ggt	atg	cgt	tac	tct	gaa	gat	cac	gcg	cag	480
Gln	Ser	Ser	Leu	Phe	Arg	Gly	Met	Arg	Tyr	Ser	Glu	Asp	His	Ala	Gln	
145							150						155			
5	atc	aaa	gag	tgg	gca	ccg	tta	gtg	atg	gaa	ggg	cgc	gat	ccg	caa	528
Ile	Lys	Glu	Trp	Ala	Pro	Leu	Val	Met	Glu	Gly	Arg	Asp	Pro	Gln	Gln	
160							165					170				
10	aaa	gtg	gca	gcc	acg	cgt	acg	gaa	att	ggt	acc	gat	gtg	aac	tac	576
Lys	Val	Ala	Ala	Thr	Arg	Thr	Glu	Ile	Gly	Thr	Asp	Val	Asn	Tyr	Gly	
175							180				185		190			
15	gag	atc	acc	cgc	cag	tta	att	gct	tcc	ttg	cag	aag	aaa	tct	aac	624
Glu	Ile	Thr	Arg	Gln	Leu	Ile	Ala	Ser	Leu	Gln	Lys	Lys	Ser	Asn	Phe	
195							200				205					
20	tcg	ctg	caa	ctc	agc	agc	gaa	gtc	cgc	gcc	cta	aag	cgt	aat	gac	672
Ser	Leu	Gln	Leu	Ser	Ser	Glu	Val	Arg	Ala	Leu	Lys	Arg	Asn	Asp	Asp	
210							215				220					
25	aac	acc	tgg	acc	gtt	acc	gtt	gcc	gat	ctg	aaa	aat	ggc	act	gca	720
Asn	Thr	Trp	Thr	Val	Thr	Val	Ala	Asp	Leu	Lys	Asn	Gly	Thr	Ala	Gln	
225							230				235					
30	aac	att	cgt	gcc	aaa	ttt	gtc	ttt	atc	ggc	gcg	ggt	gct	gct	768	
Asn	Ile	Arg	Ala	Lys	Phe	Val	Phe	Ile	Gly	Ala	Gly	Gly	Gly	Ala	Ala	Leu
240							245				250					
35	aag	ctg	tta	cag	gaa	tcg	ggg	att	ccg	gaa	gct	aaa	gac	tac	gcc	816
Lys	Leu	Leu	Gln	Glu	Ser	Gly	Ile	Pro	Glu	Ala	Lys	Asp	Tyr	Ala	Gly	
255							260				265		270			
40	ttc	ccg	gtg	ggc	gga	cag	ttc	ctt	gtt	tcg	gaa	aac	ccg	gac	gtg	864
Phe	Pro	Val	Gly	Gly	Gln	Phe	Leu	Val	Ser	Glu	Asn	Pro	Asp	Val	Val	
275							280				285					
45	aat	cac	cat	ctg	gct	aag	gtt	tac	ggt	aaa	gca	tcc	gtt	ggc	gca	912
Asn	His	His	Leu	Ala	Lys	Val	Tyr	Gly	Lys	Ala	Ser	Val	Gly	Ala	Pro	
290							295				300					
50	ccg	atg	tcg	gtt	ccg	cat	atc	gat	acc	cgc	gtt	ctg	gac	ggt	aaa	960
Pro	Met	Ser	Val	Pro	His	Ile	Asp	Thr	Arg	Val	Leu	Asp	Gly	Lys	Arg	
305							310				315					
55	gta	gtg	ctg	ttt	ggg	cca	ttt	gcc	acc	ttc	tca	acc	aaa	ttc	ctc	1008
Val	Val	Leu	Phe	Gly	Pro	Phe	Ala	Thr	Phe	Ser	Thr	Lys	Phe	Leu	Lys	
320							325				330					
60	aac	ggt	tca	ttg	tgg	gat	cta	atg	agt	tcc	acc	acc	acc	tct	aac	1056
Asn	Gly	Ser	Leu	Trp	Asp	Leu	Met	Ser	Ser	Thr	Thr	Thr	Ser	Asn	Val	
335							340				345		350			
55	atg	ccg	atg	atg	cac	gtc	ggg	ctg	gat	aat	ttc	gat	ctg	gtg	aaa	1104
Met	Pro	Met	Met	His	Val	Gly	Leu	Asp	Asn	Phe	Asp	Leu	Val	Lys	Tyr	
355							360				365					
60	ctg	gtg	agt	cag	gtg	atg	ttg	agt	gaa	gag	gat	cgt	ttt	gaa	gct	1152
Leu	Val	Ser	Gln	Val	Met	Leu	Ser	Glu	Glu	Asp	Arg	Phe	Glu	Ala	Leu	
370							375				380					

aaa gag tac tat ccg cag gcg aaa aaa gag gac tgg cgt ttg tgg caa	1200
Lys Glu Tyr Tyr Pro Gln Ala Lys Lys Glu Asp Trp Arg Leu Trp Gln	
385 390 395	
5 gcg ggg cag cgc gtg cag att atc aag cgt gat gcc gag aaa ggt ggc	1248
Ala Gly Gln Arg Val Gln Ile Ile Lys Arg Asp Ala Glu Lys Gly Gly	
400 405 410	
10 gta ctg cgt ctg ggt act gaa gtc gtc agt gac cag caa gga acc att	1296
Val Leu Arg Leu Gly Thr Glu Val Val Ser Asp Gln Gln Gly Thr Ile	
415 420 425 430	
15 gcc gcg ctc ctg ggg gca tcg cca ggg gcg tca acc gcc gcg ccg att	1344
Ala Ala Leu Leu Gly Ala Ser Pro Gly Ala Ser Thr Ala Ala Pro Ile	
435 440 445	
20 atg ttg aat ctg ctg gaa aaa gta ttt ggc gat cgt gtt tcc agc ccg	1392
Met Leu Asn Leu Leu Glu Lys Val Phe Gly Asp Arg Val Ser Ser Pro	
450 455 460	
25 caa tgg cag gct acg ttg aaa gcg atc gtt ccg tct tat gga cgc aag	1440
Gln Trp Gln Ala Thr Leu Lys Ala Ile Val Pro Ser Tyr Gly Arg Lys	
465 470 475	
30 ctg aac ggt gat gta gcg gca aca gaa cgc gag ttg cag tac acc agc	1488
Leu Asn Gly Asp Val Ala Ala Thr Glu Arg Glu Leu Gln Tyr Thr Ser	
480 485 490	
35 gaa gtg ctg ggg ttg aac tac gac aag ccg cag gca gca gat agt acg	1536
Glu Val Leu Gly Leu Asn Tyr Asp Lys Pro Gln Ala Ala Asp Ser Thr	
495 500 505 510	
ccg aaa ccg cag ttg aaa ccg caa ccc gtt caa aaa gaa gtg gcg gat	1584
Pro Lys Pro Gln Leu Lys Pro Gln Pro Val Gln Lys Glu Val Ala Asp	
515 520 525	
40 att gcg ttg taatgatacg ccacatccgg catggtatgc cggatgtggc	1633
Ile Ala Leu	
45 <210> 2	
<211> 529	
<212> PRT	
<213> Escherichia coli	
50 <400> 2	
Met Ala Ala Lys Ala Lys Ala Ser Glu Glu Gln Glu Thr Asp Val Leu	
1 5 10 15	
55 Leu Ile Gly Gly Gly Ile Met Ser Ala Thr Leu Gly Thr Tyr Leu Arg	
20 25 30	
Glu Leu Glu Pro Glu Trp Ser Met Thr Met Val Glu Arg Leu Glu Gly	
35 40 45	
60 Val Ala Gln Glu Ser Ser Asn Gly Trp Asn Asn Ala Gly Thr Gly His	
50 55 60	
Ser Ala Leu Met Glu Leu Asn Tyr Thr Pro Gln Asn Ala Asp Gly Ser	

	65	70	75	80
	Ile Ser Ile Glu Lys Ala Val Ala Ile Asn Glu Ala Phe Gln Ile Ser			
	85		90	95
5	Arg Gln Phe Trp Ala His Gln Val Glu Arg Gly Val Leu Arg Thr Pro			
	100	105		110
	Arg Ser Phe Ile Asn Thr Val Pro His Met Ser Phe Val Trp Gly Glu			
10	115	120		125
	Asp Asn Val Asn Phe Leu Arg Ala Arg Tyr Ala Ala Leu Gln Gln Ser			
	130	135	140	
15	Ser Leu Phe Arg Gly Met Arg Tyr Ser Glu Asp His Ala Gln Ile Lys			
	145	150	155	160
	Glu Trp Ala Pro Leu Val Met Glu Gly Arg Asp Pro Gln Gln Lys Val			
	165	170		175
20	Ala Ala Thr Arg Thr Glu Ile Gly Thr Asp Val Asn Tyr Gly Glu Ile			
	180	185		190
	Thr Arg Gln Leu Ile Ala Ser Leu Gln Lys Lys Ser Asn Phe Ser Leu			
25	195	200	205	
	Gln Leu Ser Ser Glu Val Arg Ala Leu Lys Arg Asn Asp Asp Asn Thr			
	210	215	220	
30	Trp Thr Val Thr Val Ala Asp Leu Lys Asn Gly Thr Ala Gln Asn Ile			
	225	230	235	240
	Arg Ala Lys Phe Val Phe Ile Gly Ala Gly Gly Ala Ala Leu Lys Leu			
	245	250		255
35	Leu Gln Glu Ser Gly Ile Pro Glu Ala Lys Asp Tyr Ala Gly Phe Pro			
	260	265	270	
	Val Gly Gly Gln Phe Leu Val Ser Glu Asn Pro Asp Val Val Asn His			
40	275	280	285	
	His Leu Ala Lys Val Tyr Gly Lys Ala Ser Val Gly Ala Pro Pro Met			
	290	295	300	
45	Ser Val Pro His Ile Asp Thr Arg Val Leu Asp Gly Lys Arg Val Val			
	305	310	315	320
	Leu Phe Gly Pro Phe Ala Thr Phe Ser Thr Lys Phe Leu Lys Asn Gly			
	325	330		335
50	Ser Leu Trp Asp Leu Met Ser Ser Thr Thr Ser Asn Val Met Pro			
	340	345	350	
	Met Met His Val Gly Leu Asp Asn Phe Asp Leu Val Lys Tyr Leu Val			
55	355	360	365	
	Ser Gln Val Met Leu Ser Glu Glu Asp Arg Phe Glu Ala Leu Lys Glu			
	370	375	380	
60	Tyr Tyr Pro Gln Ala Lys Lys Glu Asp Trp Arg Leu Trp Gln Ala Gly			
	385	390	395	400
	Gln Arg Val Gln Ile Ile Lys Arg Asp Ala Glu Lys Gly Gly Val Leu			

405 410 415

Arg Leu Gly Thr Glu Val Val Ser Asp Gln Gln Gly Thr Ile Ala Ala
420 425 430

5 Leu Leu Gly Ala Ser Pro Gly Ala Ser Thr Ala Ala Pro Ile Met Leu
435 440 445

Asn Leu Leu Glu Lys Val Phe Gly Asp Arg Val Ser Ser Pro Gln Trp
10 450 455 460

Gln Ala Thr Leu Lys Ala Ile Val Pro Ser Tyr Gly Arg Lys Leu Asn
465 470 475 480

15 Gly Asp Val Ala Ala Thr Glu Arg Glu Leu Gln Tyr Thr Ser Glu Val
485 490 495

Leu Gly Leu Asn Tyr Asp Lys Pro Gln Ala Ala Asp Ser Thr Pro Lys
500 505 510

20 Pro Gln Leu Lys Pro Gln Pro Val Gln Lys Glu Val Ala Asp Ile Ala
515 520 525

Leu
25

30 <210> 3
<211> 25
<212> DNA
<213> Artificial sequence

<220>
35 <223> Description of the artificial sequence: Primer YojH1
<400> 3
gcggaattcg atggcggcaa aagcg 25

40 <210> 4
<211> 20
<212> DNA
<213> Artificial sequence

45 <220>
<223> Description of the artificial sequence: Primer YojH2
<400> 4
50 gttacgcccc atccaaacatc 20

<210> 5
<211> 20
55 <212> DNA
<213> Artificial sequence

<220>
<223> Description of the artificial sequence: Primer Tdhl
60 <400> 5
tcgcgaccta taagtttggg 20

5 <210> 6
<211> 20
<212> DNA
<213> Artificial sequence

10 <220>
<223> Description of the artificial sequence: Primer Tdh2
<400> 6
aataccagcc cttgttcgtg 20

15 <210> 7
<211> 24
<212> DNA
<213> Artificial sequence

20 <220>
<223> Description of the artificial sequence: Primer
YOJH1a
<400> 7
ggatccgttg atgccgcgca aatc 24
25

30 <210> 8
<211> 48
<212> DNA
<213> Artificial sequence

35 <220>
<223> Description of the artificial sequence: Primer YCHIS
<400> 8
cgcgaattct tagtggtggt ggtgggtggc caacgcaata tccgcccac 48

40 <210> 9
<211> 20
<212> DNA
<213> Artificial sequence

45 <220>
<223> Description of the artificial sequence: Primer Y_01
<400> 9
gctggatgaa tggcgccgg 20

50 <210> 10
<211> 27
<212> DNA
<213> Artificial sequence

55 <220>
<223> Description of the artificial sequence: Primer Y_04
<400> 10
cgcggatccc cggttcaac gatgatg 27

<210> 11

<211> 6
<212> PRT
<213> Escherichia coli

5 <220>
<223> N-Terminus of the malate:quinone oxidoreductase protein B.

<400> 11
10 Leu Asn Ala Val Ser Met
1 5

15 <210> 12
<211> 7
<212> PRT
<213> Escherichia coli

20 <220>
<223> N-Terminus of the malate:quinone oxidoreductase protein C.

<400> 12
25 Ala Val Ser Met Ala Ala Lys
1 5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/05548

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C12N9/02 C12P13/08 C12N15/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BIOSIS, WPI Data, PAJ, EPO-Internal, EMBL, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KATHER BIRGIT ET AL: "Another unusual type of citric acid cycle enzyme in <i>Helicobacter pylori</i> : The malate:quinone oxidoreductase." JOURNAL OF BACTERIOLOGY, vol. 182, no. 11, June 2000 (2000-06), pages 3204-3209, XP002179952 ISSN: 0021-9193 tables 1,2	1-4, 25, 26
Y		5-24, 27, 28
X	DATABASE EMBL 'Online' BLATTNER F.R. ET AL.: "The complete genome sequence of <i>Escherichia coli</i> K-12." retrieved from EBI Database accession no. P33940 XP002179954 the whole document	1-4, 25, 26

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

19 October 2001

05/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax (+31-70) 340-3016

Authorized officer

Lanzrein, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/05548

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DE 198 31 609 A (KERNFORSCHUNGSAVLAGE JUELICH) 15 April 1999 (1999-04-15) page 5, line 55 -page 6, line 10	5-24
Y	EP 0 436 886 A (KERNFORSCHUNGSAVLAGE JUELICH) 17 July 1991 (1991-07-17) the whole document	6-14, 19, 20
Y	US 5 939 307 A (LIAW HUNGMING JAMES ET AL) 17 August 1999 (1999-08-17) column 7, line 42-57; claims 4,17-20	27, 28
A	MOLENAAR D ET AL: "BIOCHEMICAL AND GENETIC CHARACTERIZATION OF THE MEMBRANE-ASSOCIATED MALATE DEHYDROGENASE (ACCEPTOR) FROM CORYNEBACTERIUM GLUTAMICUM" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 254, 1998, pages 395-403, XP000941422 ISSN: 0014-2956 the whole document	1-28
A	VOGEL R F ET AL: "CLONING AND SEQUENCE OF THE MDH STRUCTURAL GENE OF ESCHERICHIA COLI CODING FOR MALATE DEHYDROGENASE" ARCHIVES OF MICROBIOLOGY, BERLIN, DE, vol. 149, 1987, pages 36-42, XP002932511 ISSN: 0302-8933 the whole document	1-28
P, X	VAN DER REST MICHEL E ET AL: "Functions of the membrane-associated and cytoplasmic malate dehydrogenases in the citric acid cycle of <i>Escherichia coli</i> ." JOURNAL OF BACTERIOLOGY, vol. 182, no. 24, December 2000 (2000-12), pages 6892-6899, XP002179953 ISSN: 0021-9193 the whole document	1-4, 25-28
P, Y	EP 1 038 969 A (DEGUSSA) 27 September 2000 (2000-09-27) the whole document	1-28
P, Y	EP 1 085 091 A (DEGUSSA) ;KERNFORSCHUNGSAVLAGE JUELICH (DE)) 21 March 2001 (2001-03-21) the whole document	1-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/05548

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
DE 19831609	A 15-04-1999	DE	19831609 A1	15-04-1999
		AU	1148299 A	27-04-1999
		BR	9813021 A	15-08-2000
		CN	1275167 T	29-11-2000
		WO	9918228 A2	15-04-1999
		EP	1015621 A2	05-07-2000
		HU	0004381 A2	28-03-2001
		SK	4812000 A3	12-09-2000
EP 0436886	A 17-07-1991	DE	3942947 A1	27-06-1991
		DE	59005821 D1	30-06-1994
		EP	0436886 A1	17-07-1991
US 5939307	A 17-08-1999	AU	730102 B2	22-02-2001
		AU	3899497 A	20-02-1998
		BR	9710503 A	11-01-2000
		CN	1226931 A	25-08-1999
		EP	0917578 A1	26-05-1999
		HU	9903856 A2	28-03-2000
		JP	2000515763 T	28-11-2000
		NO	990362 A	26-01-1999
		PL	331351 A1	05-07-1999
		TR	9900213 T2	21-04-1999
		WO	9804715 A1	05-02-1998
EP 1038969	A 27-09-2000	DE	19912384 A1	21-09-2000
		AU	2236900 A	21-09-2000
		BR	0001342 A	02-05-2001
		CN	1267734 A	27-09-2000
		EP	1038969 A2	27-09-2000
		JP	2000270888 A	03-10-2000
		SK	3742000 A3	09-10-2000
EP 1085091	A 21-03-2001	DE	19941478 A1	08-03-2001
		CN	1291651 A	18-04-2001
		EP	1085091 A1	21-03-2001
		JP	2001095592 A	10-04-2001